Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBMRNA-405 Booster in Chinese Adults
NCT05897190Phase 1Completed
- Sponsor
- Argorna Pharmaceuticals
- Start
- May 2022
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of RBMRNA-405 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Argorna Pharmaceuticals. Primary endpoint: Incidence of solicited local and systemic adverse events (AE) at 14 days. Started May 2022; status: completed.
02
Drugs
RBMRNA-405
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05897190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05897190.